Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...
People taking new weight-loss drugs say they curb cravings for booze, drugs, and nicotine. Did scientists inadvertently ...
Canada's health regulator has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
About 7.4 million Americans with obesity could have insurance coverage for drugs like Wegovy if the Trump administration ...
The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback